Sangamo BioSciences Announces Plans To Initiate A Second Clinical Trial Of CCR5-ZFP Therapeutic To Treat HIV/AIDS

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company’s ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

Source: Sangamo BioSciences Announces Plans To Initiate A Second Clinical Trial Of CCR5-ZFP Therapeutic To Treat HIV/AIDS